我不怕牺牲
发表于 2025-3-28 17:04:20
http://reply.papertrans.cn/23/2264/226396/226396_41.png
Gastric
发表于 2025-3-28 20:26:18
http://reply.papertrans.cn/23/2264/226396/226396_42.png
insolence
发表于 2025-3-29 02:34:30
http://reply.papertrans.cn/23/2264/226396/226396_43.png
vanquish
发表于 2025-3-29 04:17:29
http://reply.papertrans.cn/23/2264/226396/226396_44.png
Angioplasty
发表于 2025-3-29 07:54:57
http://reply.papertrans.cn/23/2264/226396/226396_45.png
HAUNT
发表于 2025-3-29 11:24:20
Franz Breuer,Petra Muckel,Barbara Dierishe era of tyrosine kinase inhibitors (TKI). HSCT can induce a BCR/ABL negative state with observation periods now exceeding more than 25 years in substantial numbers of patients. No other treatment so far has achieved this goal. Risk factors for outcome after HSCT are known and selection criteria ca
Agnosia
发表于 2025-3-29 16:43:32
,Gütekriterien und ethische Fragen,f CML patients who respond to TKI is now considered very close to that of the healthy population control. Several clinical trials have demonstrated that some patients with CML in chronic phase who achieve sustained deep molecular responses on TKI therapy can safely suspend therapy and attempt a new
北京人起源
发表于 2025-3-29 20:41:34
Anwendungen des RGTM-Forschungsstils,cludes immune activation and specific targeting of CML stem cells. Early studies of IFNα in CML demonstrated that it could induce extremely stable remissions, which correlated with long-term survival. Some patients even sustained their remission after discontinuing therapy, but the mechanism underly
变白
发表于 2025-3-30 02:09:37
http://reply.papertrans.cn/23/2264/226396/226396_49.png
施加
发表于 2025-3-30 06:14:54
http://reply.papertrans.cn/23/2264/226396/226396_50.png